Evidence map›Paper›PMID 36946241›Full record

ArticleESC heart failure2023

Health-related quality of life among transthyretin amyloid cardiomyopathy patients.

Per Eldhagen, Jukka Lehtonen, Einar Gude, Finn Gustafsson, Anne Bagger-Bahnsen, Merja Vakevainen, Trine Pilgaard, Dorte Wedell-Wedellsborg, Steen Hvitfeldt Poulsen, Nordic PROACT study group

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Patient-reported health status in TTR amyloidosis: which yardstick to use?Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  6. Article
  7. Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  8. Article
  9. Article
  10. Health-related quality of life is an independent predictor of mortality and hospitalisations in transthyretin amyloid cardiomyopathy: a prospective cohort study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 5 countries.

Per EldhagenDepartment of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden.
Jukka LehtonenHeart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
Einar GudeDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Finn GustafssonDepartment of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Anne Bagger-BahnsenPfizer Denmark, Ballerup, Denmark.
Merja VakevainenPfizer Finland, Helsinki, Finland.
Trine PilgaardPfizer Denmark, Ballerup, Denmark.
Dorte Wedell-WedellsborgWW Projects, Copenhagen, Denmark.
Steen Hvitfeldt PoulsenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Nordic PROACT study group
Center for Clinical & Basic Research · DKAarhus University Hospital · DKKarolinska University Hospital · SEOslo University Hospital · NOPfizer (France) · FRRigshospitalet · DKUniversity Hospital of Umeå · SEUniversity of Copenhagen · DKUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTransthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health-related quality of life (HRQoL) in ATTR CM patients. METHODS AND

resultsThe Nordic PROACT study was a cross-sectional non-interventional study conducted in 12 cardiology hospital clinics across Norway, Sweden, Finland and Denmark. Men and women aged ≥18 years diagnosed with symptomatic ATTR CM were included. The investigator provided information on medical history, biomarkers, current treatment, co-morbidities and disease severity according to the New York Heart Association (NYHA) class and the National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major Depression Inventory (MDI). A total of 169 patients (mean ± SD age 77.7 ± 6.2 years) were included. Ninety-two per cent were men. Seventy-six per cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean ± SD KCCQ score of 64.3 ± 23.1 for total symptom score, 64.8 ± 20.9 for overall summary score (OSS) and 65.1 ± 21.5 for clinical summary score. The EQ-5D-5L total utility score was 0.8 ± 0.2 and the EQ-5D-5L VAS score was 62.9 ± 20.6. The vast majority (89%) did not report any signs of depression. Patients with ATTRv CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS scores and a higher MDI score. Patients with higher NYHA classes and NAC disease stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate NYHA class remained significant (P < 0.05) after adjusting for multiple testing.

conclusionsKCCQ scores were lower than previously reported for patients with other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to NYHA class and NAC disease stage. The prevalence of depression appeared to be low.

Indexed as

CardiomyopathiesHeart DiseasesAdolescentAdultAgedAged, 80 and overFemaleHumansMalePrealbuminQuality of LifeSurveys and QuestionnairesPrealbuminAmyloidosisATTR CMCardiomyopathyObservational studyPatient-reported outcome measuresQuality of lifeTransthyretin

Identifiers

PMID36946241
PMCPMC10192258
OpenAlexW4353018188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.